Non-invasive tri-modal visualisation via PET/SPECT/μCT of recombinant human bone morphogenetic protein-2 retention and associated bone regeneration: A proof of concept

J Control Release. 2018 Sep 10:285:178-186. doi: 10.1016/j.jconrel.2018.07.012. Epub 2018 Jul 11.

Abstract

Bone morphogenetic proteins (BMP's) are vital for bone and cartilage formation, where bone morphogenetic protein-2 (BMP-2) is acknowledged as a growth factor in osteoblast differentiation. However, uncontrolled delivery may result in adverse clinical effects. In this study we investigated the possibility for longitudinal and non-invasive monitoring of implanted [125I]BMP-2 retention and its relation to ossification at the site of implantation. A unilateral critically sized femoral defect was produced in the left limb of rats while the right femur was retained intact as a paired reference control. The defect was filled with a hyaluronan hydrogel with 25% hydroxyapatite alone (carrier control; n = 2) or combined with a mixture of [125I]BMP-2 (150 μg/ml; n = 4). Bone formation was monitored using micro computed tomography (μCT) scans at 1, 3, 5, 7, 9 and 12 weeks. The retention of [125I]BMP-2 was assessed with single photon emission computed tomography (SPECT), and the bone healing process was followed with sodium fluoride (Na18F) using positron emission tomography (PET) at day 3 and at week 2, 4, and 6. A rapid burst release of [125I]BMP-2 was detected via SPECT. This was followed by a progressive increase in uptake levels of [18F]fluoride depicted by PET imaging that was confirmed as bone formation via μCT. We propose that this functional, non-invasive imaging method allows tri-modal visualisation of the release of BMP-2 and the following in vivo response. We suggest that the potential of this novel technique could be considered for preclinical evaluation of novel smart materials on bone regeneration.

Keywords: Bone morphogenetic protein 2; Bone tissue engineering; Hydrogel; Micro computed tomography; Positron emission tomography; Single-photon emission computed tomography.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Bone Morphogenetic Protein 2 / administration & dosage
  • Bone Morphogenetic Protein 2 / analysis*
  • Bone Morphogenetic Protein 2 / pharmacokinetics
  • Bone Morphogenetic Protein 2 / therapeutic use*
  • Bone Regeneration / drug effects*
  • Bone Substitutes / therapeutic use*
  • Drug Implants / therapeutic use
  • Durapatite / therapeutic use
  • Femur / diagnostic imaging*
  • Femur / drug effects
  • Femur / injuries*
  • Femur / physiology
  • Humans
  • Hyaluronic Acid / therapeutic use
  • Hydrogels / therapeutic use
  • Male
  • Positron-Emission Tomography / methods
  • Rats, Sprague-Dawley
  • Recombinant Proteins / administration & dosage
  • Recombinant Proteins / analysis
  • Recombinant Proteins / pharmacokinetics
  • Recombinant Proteins / therapeutic use
  • Tomography, Emission-Computed, Single-Photon / methods
  • Transforming Growth Factor beta / administration & dosage
  • Transforming Growth Factor beta / analysis*
  • Transforming Growth Factor beta / pharmacokinetics
  • Transforming Growth Factor beta / therapeutic use*
  • X-Ray Microtomography / methods

Substances

  • Bone Morphogenetic Protein 2
  • Bone Substitutes
  • Drug Implants
  • Hydrogels
  • Recombinant Proteins
  • Transforming Growth Factor beta
  • recombinant human bone morphogenetic protein-2
  • Hyaluronic Acid
  • Durapatite